Novel Cellular Therapy for the Treatment of Pain Associated With Chronic Pancreatitis

Eligibility Criteria

• * Age between 18 and 75 years old, male or female
• * Definite chronic pancreatitis (stage 1-3) by M-ANNHEIM criteria
• * Pancreatic calcifications
• * Moderate or marked ductal lesions
• * Marked and persistent exocrine insufficiency defined as pancreatic steatorrhea markedly reduced by enzyme supplementation
• * Typical histology of an adequate histological specimen
• * Patients who are diagnosed with painful CP for more than 6 months may be constant or may have been waxing and waning/remitting.
• * Baseline Izbicki pain score \> 50
• * Stable dose of opioids for the past 30 days
• * Acute pancreatitis per 2012 revised Atlanta criteria within the last 30 days
• * Score \>7 on the Opioid Risk Tool
• * Chronic pain syndromes other than pancreatitis that require daily use of opioids in the past 30 days.
• * Hemoglobin of \<8.0g/dL, EGFR\<60 ml/min, AST or ALT \>2 times upper limit of normal, Bilirubin \> 1.5 mg/dl unless the subject has confirmed Gilbert syndrome., Platelets \<100,000/microliter, HbA1c \>10%
• * Congestive Heart Failure NYHA class \>1
• * History of Malignancy except for in situ malignancies that have been surgically treated and basal cell skin cancers
• * Evidence of active infection using current antibiotics or with Hepatitis B, C, or HIV
• * Known intravenous contrast allergy causing anaphylaxis
• * TWEAK score \> 2 points at screening (24) (the questions below will be asked of the subjects at screening)
• * Any subject who has received an investigational drug or device within 30 days before randomization or who is expected to receive an investigational drug or device during this study.
• * Patients with planned endoscopic or surgical intervention, surgical resection or needle drainage of pancreatic structures in the next 6 months.
• * Subjects with infected pancreatic pseudocysts or pancreatic walled-off necrotic areas at the time of consent
• * Females who are pregnant or women of childbearing potential (WOCBP) and males with female partners of childbearing potential who are not willing to use adequate contraception during the study
• * Breastfeeding females
• * Subject unwilling to follow the protocol and assessments